' Fears Allayed ' by Latest Infliximab Biosimilar Evidence ' Fears Allayed ' by Latest Infliximab Biosimilar Evidence
The biosimilar is noninferior to the originator infliximab in patients with stable Crohn ' s disease, ulcerative colitis, and other inflammatory conditions, two studies demonstrate.Medscape Medical News
Source: Medscape Gastroenterology Headlines - Category: Gastroenterology Tags: Gastroenterology News Source Type: news
More News: Crohn's Disease | Gastroenterology | Inflammatory Bowel Disease | Remicade | Study | Ulcerative Colitis